表紙
市場調查報告書
商品編碼
1065223

PEG化蛋白質的全球市場(2022年∼2029年)

Global PEGylated Proteins Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球PEG化蛋白質市場相關調查分析,提供市場動態,產業分析,市場分析,競爭情形等系統性資訊。

目錄

第1章 全球PEG化蛋白質的調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球PEG化蛋白質市場-市場定義和概要

第3章 全球PEG化蛋白質市場-摘要整理

  • 市場明細:各產品類型
  • 市場明細:各應用領域
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 全球PEG化蛋白質市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球PEG化蛋白質市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • PEST分析

第6章 全球PEG化蛋白質市場-COVID-19分析

  • 市場COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後的市場方案/未來市場方案
  • COVID-19的價格的動態
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球PEG化蛋白質市場:各產品類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各產品類型
    • 市場魅力指數:各產品類型
  • 消耗品*
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • PEG化試劑
    • 單功能線性 PEG
    • 雙功能 PEG
    • 多臂 PEG
    • 支鏈 PEG
    • 其他的PEG化試劑
  • PEG化套件
  • 服務

第8章 全球PEG化蛋白質市場:各蛋白質類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各蛋白質類型
    • 市場魅力指數:各蛋白質類型
  • 細胞聚落刺激因子*
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • 干擾素
  • 促血紅細胞生長素
  • mAbs
  • 重組型第八凝血因子
  • 其他

第9章 全球PEG化蛋白質市場:各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%):各終端用戶
    • 市場魅力指數:各終端用戶
  • 製藥企業及生物科技企業*
    • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2020年∼2028年)
  • CRO
  • 學術研究設施

第10章 全球PEG化蛋白質市場:各地區

  • 簡介
    • 市場規模分析,100萬美元(2020年∼2029年),及與前一年同期比較成長分析(%)(2020年∼2028年):各地區
    • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第11章 全球PEG化蛋白質市場-競爭情形

  • 競爭模式
  • 主要的開發與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 顛覆性技術的企業

第12章 全球PEG化蛋白質市場-企業簡介概要

  • Thermo Fisher Scientific Inc*
    • 企業概要
    • 產品系列及說明
    • 主要亮點
    • 財務概要
  • Merck KGaA
  • NOF America Corporation
  • JenKem Technology USA Inc
  • Creative PEGworks
  • Celares GmbH
  • Quanta BioDesign, Ltd

第13章 全球PEG化蛋白質市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
目錄
Product Code: DMPH4857

Market Overview

The global PEGylated proteins market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

PEGylation is the process of binding or alteration of biological molecules by conjugation with polyethylene glycol is known as PEGylation. PEGylation enhances the stability and solubility of the drug and declines immunogenicity by changing the molecule's electrostatic binding, confirmation, and hydrophobicity.

Market Dynamics

The global PEGylated proteins market growth is driven by the increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing in adoption of protein-based drugs over non-protein-based drugs and increase of protein stability and circulating half-life with the help of PEGylation are the major drivers of market.

Increasing adoption of PEGylated protein-based drugs is expected to hold the largest share in this market segment

Increasing adoption of PEGylated protein-based drugs due to increased stability and circulating half-life, and awareness on strategies to improve protein stability and circulating half-life, are expected to boost the market growth during the forecast period. For instance, Mabwell Bioscience Co., Ltd., in September 2020, began the phase III clinical study to investigate the immunogenicity, safety, and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in the patients who were previously left untreated and meet the requirements of being less than 6 years old and have severe hemophilia A. In addition, the increasing adoption of PEGylated protein to treat various chronic diseases will further fuel the market, as the number of people infected with chronic disease is on a rise. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020.

Failures in drug development is likely to hinder the market growth

The development of drugs is a complex and challenging process. The chances of a drug being developed during the first trial are rare as failures in drug development are very prevalent. The overall failure rate in drug development is around 96%, including a 90% failure rate during clinical development. The consequence of an expensive drug failure for pharmaceutical companies ranges from site closures, loss of jobs, and exhausting research and development budgets. Thus, failures in drug development and rising recalls of the therapeutic drugs might hamper the growth of the PEGylated proteins market during the forecast period.

COVID-19 Impact Analysis

The outbreak of coronavirus did not adversely affect the PEGylated Proteins Market. The demand for PEGylated proteins remained unaffected as they fall under necessities. Several research institutes conducted extensive research based on PEGylation technology in 2020. For instance, in a research study published in the Journal of General Virology, 2020, SARS-CoV-2 replication could be inhibited by low concentrations of PEG-IFN-alpha-2a that inhibit MERS-CoV replication in cell culture. The impact of COVID-19 on the PEGylated proteins market was minimal.

Segment Analysis

The colony-stimulating factors segment is expected to hold the largest share in this market segment

Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors but have a role in stimulating blood cells, and hence, these factors can be beneficial in supporting a person's immune system during cancer treatment. The increasing incidence of cancer across the globe has increased the demand for this segment, which will fuel the market growth for PEGylated proteins globally. According to Global cancer statistics, 2020, the number of cancer cases globally was estimated to be 19, 292,789, with nearly 9,958,133 deaths due to cancer. Thus, the need for colony-stimulating factors to effectively treat cancer will drive market growth.

Geographical Analysis

North America region holds the largest market share of global PEGylated proteins market

The North American region is expected to dominate the overall PEGylated protein market throughout the forecast period. The presence of key players, the high prevalence of chronic diseases in the region, established healthcare infrastructure, and growing awareness of advanced treatment options among the American population are key factors for its large share in the market. In this region, the United States holds the largest market share, and the large patient pool in the country is anticipated to stimulate the demand in this region. According to Globocan 2020, nearly 2,281,658 cancer cases were diagnosed in 2020, and cancer led to 612,390 deaths in the United States during the year. Breast cancer accounted for 253,465 new cases in 2020, followed by lung (227,875), prostate (209,512), and colon (101,809) cancers in the United States.

Moreover, the increasing geriatric population and the high incidence of chronic diseases are also expected to play a vital role in the growth of the studied market. According to the Population Reference Bureau's Population Bulletin: Aging in the United States, the total number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. Thus, the elderly population is more prone to chronic diseases, which surges the demand for advanced diagnostics and treatment planning.

Competitive Landscape

The global PEGylated proteins market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA Inc., Creative PEGworks, and Celares GmbH, Quanta BioDesign, Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In August 2021, JenKem Technology provides large scale GMP manufacture of PEG derivatives for Lipid Nanoparticles (LNPs), and related PEG intermediates.

Global PEGylated Proteins Market - Key Companies to Watch

Thermo Fisher Scientific Inc

Overview: Thermo Fisher Scientific is global manufacturer and provider of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry. The company generated revenue of USD 32.3 billion in 2020, and invested USD 1.2 billion in R&D.

Product Portfolio: It offers thermo Scientific Pierce MS(PEG)n reagents are methyl-terminated, polyethylene glycol compounds (n equals 4 to 24 PEG units) activated as NHS esters for covalent pegylation of primary amines on proteins (e.g., lysines) or assay surfaces.

Why Purchase the Report?

Visualize the composition of the PEGylated proteins market segmentation by product type, protein type, end-user and region highlighting the key commercial assets and players.

Identify commercial opportunities in PEGylated proteins market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of PEGylated proteins market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players.

The global PEGylated proteins market report would provide an access to an approx. 46 market data table, 56 figures and 200 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global PEGylated Proteins Market - By Product Type

Consumables

PEGylation Reagents

Monofunctional Linear PEGs

Bifunctional PEGs

Multi-Arm PEGs

Branched PEGs

Other PEGylation Reagents

PEGylation Kits

Services

Global PEGylated Proteins Market - By Protein Type

Colony Stimulating Factors

Interferons

Erythropoietin

mAbs

Recombinant Factor VIII

Other Protein Type

Global PEGylated Proteins Market - By End-User

Pharmaceutical & Biotechnology Companies

CROs

Academic Research Institutes

Global PEGylated Proteins Market - By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global PEGylated Proteins Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global PEGylated Proteins Market - Market Definition and Overview

3. Global PEGylated Proteins Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global PEGylated Proteins Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Increasing adoption of PEGylated protein-based drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. Failures in drug development
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global PEGylated Proteins Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. PEST Analysis

6. Global PEGylated Proteins Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global PEGylated Proteins Market - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. PEGylation Reagents
    • 7.3.1. Monofunctional Linear PEGs
    • 7.3.2. Bifunctional PEGs
    • 7.3.3. Multi-Arm PEGs
    • 7.3.4. Branched PEGs
    • 7.3.5. Other PEGylation Reagents
  • 7.4. PEGylation Kits
  • 7.5. Services

8. Global PEGylated Proteins Market - By Protein Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 8.1.2. Market Attractiveness Index, By Protein Type
  • 8.2. Colony Stimulating Factors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Interferons
  • 8.4. Erythropoietin
  • 8.5. mAbs
  • 8.6. Recombinant Factor VIII
  • 8.7. Other Protein Type

9. Global PEGylated Proteins Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Pharmaceutical & Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. CROs
  • 9.4. Academic Research Institutes

10. Global PEGylated Proteins Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global PEGylated Proteins Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Key Developments and Strategies
  • 11.3. Company Share Analysis
  • 11.4. Product Benchmarking
  • 11.5. Key Companies to Watch
  • 11.6. Company with disruptive technology

12. Global PEGylated Proteins Market- Company Profiles

  • 12.1. Thermo Fisher Scientific Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. NOF America Corporation
  • 12.4. JenKem Technology USA Inc
  • 12.5. Creative PEGworks
  • 12.6. Celares GmbH
  • 12.7. Quanta BioDesign, Ltd

LIST NOT EXHAUSTIVE

13. Global PEGylated Proteins Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us